Stryker Corporation (SYK) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Stryker Corporation stock $374, price $335, upside +11.5%, quality 68 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range $181.11 – $398.20 · fair‑value band $234.62 – $467.00 · the $335.08 price screens below the $373.62 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Stryker in your weekly email
Every Wednesday you see whether Stryker is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics.
Show moreShow less
The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products.
The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications.
The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Stock analysis
Stryker Corporation (SYK) currently trades at $335.08, while our model-based Fair Value estimate is $373.62, implying the stock looks roughly 10% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $212.39 per share, and 0 of the 24 models we run sit above the $335.08 price.
Bear case: the Dividend Discount group reads lowest at $56.29, and 24 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: $234.62 (bear) to $467.00 (bull), the price of $335.08 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Stryker Corporation reported revenue of $25.1B in FY2025 versus $17.1B in FY2021, a compound +10.1%/yr. Reported net income was $3.2B in FY2025, compounding +13.0%/yr from FY2021.
Key figures
Market cap $129B Large · P/E ratio 35.7 · P/S ratio 4.92 · EPS (TTM) $9.39 · Dividend yield 0.3% · Net margin 13.8% · Return on equity 16.0% · Return on assets (EBIT) 10.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 65 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 13% below its 52-week high and 25% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −17% fair-value upside, at 12%, SYK screens cheaper than that median.
Fair Value models
Bear$234.62Fair Value $373.62Bull$467.00
Price $335.08 · Upside +11.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($7.23 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
SaleWilliam E Berry JrVP, Chief Accounting Officer1,953 shares at $365.49$713,802Nov 14, 2025
Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+11.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
Start year 2020 (pandemic). Over 10 years: +9.7% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+14.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+13.7%
Dividend (yield on the price)0.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.10.2% vs 8.4%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 20%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+16.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +13.3% a year for the price and +5.1% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Stryker shows reasonable profitability supported by ongoing launches of surgeon-focused tools, yet its main weakness remains limited public signals of durable competitive advantages amid persistent operational constraints.
Main risk: Existing competitors and new entrants may integrate AI, robotics and machine learning into their product offerings more quickly than Stryker, which could erode its market share in orthopaedics and robotics-assisted procedures.
Bull case: Stryker could strengthen its position in orthopaedics and expand adoption of its Mako platform across more procedure types and settings by accelerating its own integration of AI and robotics through continued R&D and targeted acquisitions.
Bear case: If competitors integrate AI, robotics and machine learning more rapidly, Stryker could lose meaningful market share in its core orthopaedics and robotics businesses as hospitals and surgeons shift to rival platforms.
Stryker keeps rolling out surgeon-shaped tools like the newly cleared Sonopet 3 platform, yet supply shortfalls in its peripheral vascular business have dragged on past the expected third-quarter fix and into the fourth. The same constraints that created backorders and missed sales earlier this year still limit the ability to win new business and support full customer inventory. Will the steady flow of product launches overcome these execution hurdles, or do the operational fixes need to land first?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 321 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside+11.5% · Top 25%
Profitability
Return on equity (12 months)16.0% · Top 25%
Return on assets6.8% · Above median
Net margin (12 months)13.8% · Above median
Operating margin (12 months)20.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)7.6% · Above median
Dividend yield (12 months)0.3% · Bottom 25%
Balance sheet
Debt / equity0.66× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)35.7× · Pricier than median
P/B5.77× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)4.92× · Pricier than median
Price / free cash flow (fiscal year)30.2× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Stryker Corporation Fair Value". https://www.fairvalue-calculator.com/stock/SYK
Frequently asked questions
Is Stryker Corporation (SYK) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $373.62 versus a price of $335.08, about +12% upside (undervalued).
What is the fair value of SYK?
Our model-based fair value for Stryker Corporation is $373.62 (as of Nov 5, 2026), built from audited fundamentals. The current price: $335.08.
What is the quality score of SYK?
Stryker Corporation has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Stryker Corporation (SYK)?
Our model-based price target is the fair value of $373.62 (as of Nov 5, 2026) from 24 valuation models. Cautious scenario $234.62, optimistic scenario $467.00. It is a calculation from audited fundamentals, not an analyst target.
What is the Stryker Corporation stock forecast for 2026?
Our models put fair value at $373.62, about +12% upside versus a price of $335.08 (undervalued). Cautious scenario $234.62, optimistic scenario $467.00. The calculation is refreshed regularly with new filings.
What is the revenue of Stryker Corporation (SYK)?
Stryker Corporation reported trailing-twelve-month revenue of about $26.3B (latest available figure, as of Nov 5, 2026).
Does Stryker Corporation pay a dividend?
Stryker Corporation currently shows a dividend yield of 0.26% relative to its recent price (as of Nov 5, 2026).
What growth is priced into Stryker Corporation (SYK)?
For today's price to be fair in a discounted-cash-flow model, Stryker Corporation would have to grow free cash flow by +16.0 % per year for five years (discount rate 8.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.8 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of SYK use?
Our models discount Stryker Corporation at 8.7 %: a base by market capitalisation (large), damped by beta 0.78, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Stryker Corporation that is +16.0 % per year a year over ten years, using the same discount rate (8.7 %) and the same formula as our fair value.
How much growth has Stryker Corporation (SYK) delivered so far?
Over the past 5 years revenue at Stryker Corporation grew +11.8 % a year. The price currently implies +16.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Stryker Corporation (SYK) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Stryker Corporation (+16.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Stryker Corporation (SYK)?
The free-cash-flow yield on the price is 3.31 %: that much free cash flow Stryker Corporation produces per unit of market value. When it exceeds the discount rate of our models (8.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Stryker Corporation (SYK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Stryker Corporation it is $373.62 per share (as of Nov 5, 2026), against a price of $335.08. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Stryker Corporation stock overvalued or undervalued in 2026?
As of Nov 5, 2026, SYK trades below its calculated fair value: price $335.08, fair value $373.62, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SYK?
No. The price is what the market pays today ($335.08); the fair value is what the company's own numbers justify ($373.62). For Stryker Corporation the two are $38.54 per share apart. That gap is exactly why we show both numbers side by side.
How much is Stryker Corporation worth?
The market values Stryker Corporation at about $129B (market capitalisation, as of Nov 5, 2026). Per share that is $335.08; our models calculate a fair value of $373.62 per share.
What do the bullish and bearish scenarios say about SYK?
Our models span a range for Stryker Corporation: cautious scenario $234.62, base $373.62, optimistic $467.00 per share (as of Nov 5, 2026, price $335.08). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SYK?
Stryker Corporation trades at a price-to-earnings ratio of 35.7 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $373.62 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 32.0 (reported for FY2025: 39.5). Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, 5 of the years ex one-offs: 37.4. Other multiples: PEG 1.4, P/B 5.8, P/S 4.9, EV/EBITDA 18.4.
What is the PEG ratio of SYK?
The PEG ratio of Stryker Corporation is 1.37 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Stryker Corporation (SYK)?
Balance-sheet figures for Stryker Corporation (as of Nov 5, 2026): return on equity 16.0%, debt of 0.66 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is SYK from its 52-week high?
Stryker Corporation trades at $335.08, about 13% below its 52-week high of $384.17 and 25% above the low of $268.90 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $373.62 is for.
Which stocks are comparable to Stryker Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Stryker Corporation stock attractive at the current price?
The data as of Nov 5, 2026: price $335.08, calculated fair value $373.62 (+12%), Quality Score 68/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SYK calculated?
We run Stryker Corporation through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $373.62, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Stryker Corporation currently trades 10% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Stryker Corporation (SYK)?
The closing price on Nov 5, 2026 was $335.08. Our model-based fair value is $373.62, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Stryker Corporation right now?
A fairly wide model range ($234.62 to $467.00) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Stryker Corporation (SYK) come from?
Earnings per share at Stryker Corporation grew +11.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +9.1 %, EBIT margin −1.0 %, tax rate +0.8 %, residual (interest, one-offs) +2.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Stryker Corporation
How large is the market capitalisation of Stryker Corporation (SYK)?
The market capitalisation of Stryker Corporation is $129B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Stryker Corporation (SYK)?
The price-to-sales ratio of Stryker Corporation is 4.92 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Stryker Corporation (SYK)?
Earnings per share at Stryker Corporation are $9.39 (price ÷ EPS = P/E 35.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Stryker Corporation (SYK)?
The dividend yield of Stryker Corporation is 0.3% (payout 7.6%, on adjusted earnings, reported 9.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Stryker Corporation (SYK)?
The net margin of Stryker Corporation is 13.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Stryker Corporation (SYK)?
The return on equity (ROE) of Stryker Corporation is 16.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Stryker Corporation (SYK)?
On an EBIT basis the return on assets of Stryker Corporation is 10.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Stryker Corporation (SYK)?
The operating margin of Stryker Corporation is 20.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Stryker Corporation (SYK)?
Revenue at Stryker Corporation is growing +7.6% versus a year earlier (3y avg +10.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Stryker Corporation (SYK)?
Earnings per share at Stryker Corporation are growing −11.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Stryker Corporation (SYK) carry?
The net debt of Stryker Corporation is $10.8B (fiscal year 2025, ≈ 2.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Stryker Corporation in the live analysis
One click puts Stryker Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 5, 2026